Evaluation of Failure Patterns Using Trimodality in Non-Small Cell Lung Cancer

Area of Science:

• Thoracic Oncology
• Surgical Oncology
• Radiation Oncology

Background:

• The efficacy of trimodality therapy for non-small cell lung cancer (NSCLC) remains a subject of debate.
• Stage III NSCLC presents a complex treatment challenge.

Purpose of the Study:

• To compare the effectiveness of chemoradiation alone versus trimodality therapy (neoadjuvant chemoradiation followed by surgery) in patients with stage III NSCLC.
• To analyze overall survival and patterns of failure in different treatment groups.

Main Methods:

• Retrospective analysis of 92 patients with stage III NSCLC.
• Comparison of overall survival (OS) and recurrence rates between patients receiving chemoradiation alone and those undergoing trimodality treatment.

Main Results:

• Trimodality therapy demonstrated significantly higher 2, 3, and 5-year OS rates (56.4%, 40.4%, 32.3%) compared to chemoradiation alone (19.7%, 15.7%, 4.5%).
• Median survival was substantially longer with trimodality therapy (34.0 months) versus chemoradiation alone (11.0 months).
• Recurrence rates were 61.8% for chemoradiation alone versus 50.0% for trimodality therapy, with different patterns of distant metastasis.

Conclusions:

• Trimodality therapy should be strongly considered for stage IIIA and potentially stage IIIB NSCLC patients with good performance status.
• This multimodal approach offers a survival benefit over standard chemoradiation for select NSCLC patients.